{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:11:42Z","timestamp":1791472302548,"version":"4.3.4"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The treatment of nonmetastatic HER2-positive breast cancer with residual invasive disease using concurrent Trastuzumab emtansine (T-DM1) and radiotherapy appears to be an effective option. Our aim was to evaluate the acute side effects of this treatment regime.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Fourteen patients were treated between March 2019 and April 2020 concurrent T-DM1 and radiotherapy. Left ventricular ejection fraction was assessed at baseline, before and after radiotherapy. All toxicities were evaluated using Common Terminology Criteria of Adverse Events (CTCAE) version 3.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The median age was 55 years (range 36 to 72). All patients received total dose of 50\u2009Gy for the breast\/ chest wall, 10 patients got lymph node irradiation, 4 patients received an additional tumor bed boost. The most common side effect was grade 1 radiodermatitis. A reversible grade 2 left ventricular ejection fraction decrease occurred in 2 patients. During our examination 3 patients showed alanine aminotransferases increase after the cycle 4 of T-DM1, 1 patient had grade 1, 1 patient grade 2, and 1 patient grade 3 alanine aminotransferase increases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The acute toxicity rate especially focusing on skin and cardiac toxicity were assumed acceptable in our cohort. To safely administer this concomitant treatment, further examination and prospective data are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/coc.0000000000000769","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T08:08:49Z","timestamp":1602058129000},"page":"895-901","source":"Crossref","is-referenced-by-count":29,"title":["Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer"],"prefix":"10.1097","volume":"43","author":[{"given":"Zita","family":"Zolcs\u00e1k","sequence":"first","affiliation":[{"name":"Radiation Oncology"},{"name":"Department of Radiation Oncology, Uzsoki Hospital, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Loirat","sequence":"additional","affiliation":[{"name":"Medical Oncology, Institut Curie, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Fourquet","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlia M.","family":"Kirova","sequence":"additional","affiliation":[{"name":"Radiation Oncology"},{"name":"Medical Department, University Versailles, St Quentin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science (New York, NY)"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science (New York, NY)"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.1993.11.10.1936","article-title":"Clinical significance of HER-2\/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group","volume":"11","author":"Seshadri","year":"1993","journal-title":"J Clin Oncol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"R9-20230903","first-page":"1829","article-title":"Antibody to HER-2\/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells","volume":"9","author":"Pietras","year":"1994","journal-title":"Oncogene"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer research"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Dieras","year":"2017","journal-title":"Lancet Oncol"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"key":"R18-20230903","first-page":"552","article-title":"NCCN guidelines updates: breast cancer","volume":"17","author":"Telli","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups","volume":"29","author":"Untch","year":"2011","journal-title":"J Clin Oncol"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"R23-20230903","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-3980","article-title":"FDA approval summary: Ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer","author":"Wedam","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R24-20230903","first-page":"183","article-title":"NCCN Guideline update: breast cancer version 1.2004","volume":"2","year":"2004","journal-title":"J Natl Compr Canc Netw"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2014.11.030","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer","volume":"114","author":"Offersen","year":"2015","journal-title":"Radiother Oncol"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1245\/s10434-014-3605-x","article-title":"Cost implications of the SSO-ASTRO consensus guideline on margins for breast-conserving surgery with whole breast irradiation in stage I and II invasive breast cancer","volume":"21","author":"Greenup","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.canrad.2015.03.009","article-title":"Irradiation of internal mammary nodes: state of the art","volume":"19","author":"Kirova","year":"2015","journal-title":"Cancer Radiother"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijrobp.2017.01.205","article-title":"Long-term results of a highly performing conformal electron therapy technique for chest wall irradiation after mastectomy","volume":"98","author":"Grellier Adedjouma","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ijrobp.2007.05.007","article-title":"Postmastectomy electron beam chest wall irradiation in women with breast cancer: a clinical step toward conformal electron therapy","volume":"69","author":"Kirova","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.meddos.2011.03.002","article-title":"Simplified field-in-field technique for a large-scale implementation in breast radiation treatment","volume":"37","author":"Fournier-Bidoz","year":"2012","journal-title":"Med Dosim"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0971-6203.54849","article-title":"Technique alternatives for breast radiation oncology: conventional radiation therapy to tomotherapy","volume":"34","author":"Fournier-Bidoz","year":"2009","journal-title":"J Med Phys"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.canrad.2020.07.001","article-title":"Radio-induced cardiotoxicity: from physiopathology and risk factors to adaptation of radiotherapy treatment planning and recommended cardiac follow-up","volume":"24","author":"Kirova","year":"2020","journal-title":"Cancer Radiother"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2147\/OTT.S156066","article-title":"The incidence of postoperative radiotherapy-induced acute dermatitis in breast cancer and its influencing factors for Chinese women","volume":"11","author":"Ding","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpainsymman.2019.03.017","article-title":"The impact of radiodermatitis on breast cancer patients\u2019 quality of life during radiotherapy: a prospective cohort study","volume":"58","author":"Fuzissaki","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"R36-20230903","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/1754-9485.12943","article-title":"Radiation-induced oesophagitis in breast cancer: factors influencing onset and severity for patients receiving supraclavicular nodal irradiation","volume":"64","author":"West","year":"2020","journal-title":"J Med Imaging Radiat Oncol"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11864-019-0646-1","article-title":"Cardiotoxicity of contemporary breast cancer treatments","volume":"20","author":"Lee Chuy","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"R38-20230903","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2019.11.023","article-title":"Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: pooled analysis in advanced HER2-positive breast cancer","volume":"126","author":"Ponde","year":"2020","journal-title":"Eur J Cancer"},{"key":"R39-20230903","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2013.54.4999","article-title":"Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis","volume":"32","author":"Dieras","year":"2014","journal-title":"J Clin Oncol"},{"key":"R40-20230903","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10549-020-05577-7","article-title":"Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane\/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis","volume":"180","author":"Paracha","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"R41-20230903","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1535-7163.MCT-15-0580","article-title":"Ado-Trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity","volume":"15","author":"Yan","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"R42-20230903","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10549-014-3166-5","article-title":"Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study","volume":"148","author":"Jacob","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"R43-20230903","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","article-title":"Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831","volume":"27","author":"Halyard","year":"2009","journal-title":"J Clin Oncol"},{"key":"R44-20230903","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2010.08.013","article-title":"The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study","volume":"47","author":"Caussa","year":"2011","journal-title":"Eur J Cancer"},{"key":"R45-20230903","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.radonc.2013.10.038","article-title":"Whole breast radiotherapy in the lateral decubitus position: a dosimetric and clinical solution to decrease the doses to the organs at risk (oar)","volume":"110","author":"Kirova","year":"2014","journal-title":"Radiother Oncol"},{"key":"R46-20230903","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ctrv.2010.08.007","article-title":"Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment","volume":"37","author":"Chargari","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"R47-20230903","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ijrobp.2020.02.017","article-title":"Should we move beyond mean heart dose?","volume":"107","author":"Loap","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:08:52Z","timestamp":1693699732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000769"}},"subtitle":["Single-center Preliminary Results"],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000769","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,6]]}}}